Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 3 (March)

1. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen.
   Clin Chem, 51(3): 532-9. [Abstract] [Full-text]
2. Neoxanthin and fucoxanthin induce apoptosis in PC-3 human prostate cancer cells.
   Cancer Lett, 220(1): 75-84. [Abstract] [Full-text]
3. Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells.
   Eur J Cancer, 41(4): 624-34. [Abstract] [Full-text]
4. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
   Eur J Cancer, 41(4): 502-7. [Abstract] [Full-text]
5. Genetic susceptibility to prostate, breast, and colorectal cancer among Nordic twins.
   Biometrics, 61(1): 55-63. [Abstract] [Full-text]
6. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
   Photochem Photobiol, 81(1): 96-105. [Abstract] [Full-text]
7. Serum alpha-tocopherol and gamma-tocopherol in relation to prostate cancer risk in a prospective study.
   J Natl Cancer Inst, 97(5): 396-9. [Abstract] [Full-text]
8. Association of a genetic polymorphism of the E-cadherin gene with prostate cancer in a Japanese population.
   Jpn J Clin Oncol, 35(3): 158-61. [Abstract] [Full-text]
9. Novel electrical detection of label-free disease marker proteins using piezoresistive self-sensing micro-cantilevers.
   Biosens Bioelectron, 20(10): 1932-8. [Abstract] [Full-text]
10. Complications of transrectal versus transperineal prostate biopsy.
    ANZ J Surg, 75(1): 48-50. [Abstract] [Full-text]
11. Antagonist of growth hormone-releasing hormone induces apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway.
    Proc Natl Acad Sci U S A, 102(9): 3435-40. [Abstract] [Full-text]
12. Pomegranate (Punica granatum) pure chemicals show possible synergistic inhibition of human PC-3 prostate cancer cell invasion across Matrigel.
    Invest New Drugs, 23(2): 121-2. [Abstract] [Full-text]
13. BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF.
    Mol Cell Biol, 25(6): 2200-15. [Abstract] [Full-text]
14. Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy.
    Am J Clin Pathol, 123(4): 553-61. [Abstract] [Full-text]
15. Mass spectral analyses of labile DOTA-NHS and heterogeneity determination of DOTA or DM1 conjugated anti-PSMA antibody for prostate cancer therapy.
    J Pharm Sci, 94(4): 788-97. [Abstract] [Full-text]
16. Beliefs about illness and quality of life among men with erectile dysfunction.
    Int J Impot Res, 17(2): 142-7. [Abstract] [Full-text]
17. Prospective study of quantitation of plasma DNA levels in the diagnosis of malignant versus benign prostate disease.
    Clin Cancer Res, 11(4): 1394-9. [Abstract] [Full-text]
18. Social disparities and prostate cancer: mapping the gaps in our knowledge.
    Cancer Causes Control, 16(1): 45-53. [Abstract] [Full-text]
19. Pilot study: potential role of vitamin D (Cholecalciferol) in patients with PSA relapse after definitive therapy.
    Nutr Cancer, 51(1): 32-6. [Abstract] [Full-text]
20. Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.
    Med Dosim, 30(1): 25-30. [Abstract] [Full-text]
21. Impact of setup uncertainty in the dosimetry of prostate and surrounding tissues in prostate cancer patients treated with Peacock/IMRT.
    Med Dosim, 30(1): 1-7. [Abstract] [Full-text]
22. Constructions of masculinity following prostatectomy-induced impotence.
    Soc Sci Med, 60(10): 2249-59. [Abstract] [Full-text]
23. Ultraviolet radiation: effects on risks of prostate cancer and other internal cancers.
    Mutat Res, 571(1): 207-19. [Abstract] [Full-text]
24. Osteoporosis risk and interest in strength training in men receiving androgen ablation therapy for locally advanced prostate cancer.
    J Am Acad Nurse Pract, 17(3): 113-22. [Abstract] [Full-text]
25. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
    Cancer Res, 65(5): 1941-51. [Abstract] [Full-text]
26. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Cancer Res, 65(5): 1849-57. [Abstract] [Full-text]
27. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
    Cancer Res, 65(5): 1761-9. [Abstract] [Full-text]
28. Osteoprotegerin in prostate cancer bone metastasis.
    Cancer Res, 65(5): 1710-8. [Abstract] [Full-text]
29. Cannabinoid receptor as a novel target for the treatment of prostate cancer.
    Cancer Res, 65(5): 1635-41. [Abstract] [Full-text]
30. Gamma-tocopherol induces apoptosis in androgen-responsive LNCaP prostate cancer cells via caspase-dependent and independent mechanisms.
    Ann N Y Acad Sci, 1031: 399-400. [Abstract] [Full-text]
31. Gamma-tocotrienol metabolism and antiproliferative effect in prostate cancer cells.
    Ann N Y Acad Sci, 1031: 391-4. [Abstract] [Full-text]
32. Inverse treatment planning based on MRI for HDR prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1267-75. [Abstract] [Full-text]
33. Use of deformed intensity distributions for on-line modification of image-guided IMRT to account for interfractional anatomic changes.
    Int J Radiat Oncol Biol Phys, 61(4): 1258-66. [Abstract] [Full-text]
34. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Int J Radiat Oncol Biol Phys, 61(4): 1251-7. [Abstract] [Full-text]
35. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1216-26. [Abstract] [Full-text]
36. Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum.
    Int J Radiat Oncol Biol Phys, 61(4): 1035-44. [Abstract] [Full-text]
37. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy.
    Int J Radiat Oncol Biol Phys, 61(4): 1019-34. [Abstract] [Full-text]
38. Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1011-8. [Abstract] [Full-text]
39. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Int J Radiat Oncol Biol Phys, 61(4): 1003-10. [Abstract] [Full-text]
40. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Int J Radiat Oncol Biol Phys, 61(4): 993-1002. [Abstract] [Full-text]
41. Prostate motion and isocenter adjustment from ultrasound-based localization during delivery of radiation therapy.
    Int J Radiat Oncol Biol Phys, 61(4): 984-92. [Abstract] [Full-text]
42. Application of the No Action Level (NAL) protocol to correct for prostate motion based on electronic portal imaging of implanted markers.
    Int J Radiat Oncol Biol Phys, 61(4): 969-83. [Abstract] [Full-text]
43. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression.
    Cancer, 103(6): 1186-94. [Abstract] [Full-text]
44. Fulminant hepatic failure secondary to metastatic prostate cancer.
    Urol Int, 74(2): 185-7. [Abstract] [Full-text]
45. Antisense inhibition of methylenetetrahydrofolate reductase reduces cancer cell survival in vitro and tumor growth in vivo.
    Clin Cancer Res, 11(5): 2047-52. [Abstract] [Full-text]
46. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism.
    Clin Cancer Res, 11(5): 1999-2007. [Abstract] [Full-text]
47. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Clin Cancer Res, 11(5): 1854-62. [Abstract] [Full-text]
48. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.
    Clin Cancer Res, 11(5): 1815-20. [Abstract] [Full-text]
49. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth.
    Clin Cancer Res, 11(5): 1704-12. [Abstract] [Full-text]
50. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
    Mol Cancer Res, 3(2): 110-8. [Abstract] [Full-text]
51. Apigenin drives the production of reactive oxygen species and initiates a mitochondrial mediated cell death pathway in prostate epithelial cells.
    Prostate, 63(2): 131-42. [Abstract] [Full-text]
52. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
    Prostate, 63(2): 143-54. [Abstract] [Full-text]
53. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Prostate, 63(2): 155-68. [Abstract] [Full-text]
54. Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines.
    Prostate, 63(2): 187-97. [Abstract] [Full-text]
55. Regulation of expression of the early growth response gene-1 (EGR-1) in malignant and benign cells of the prostate.
    Prostate, 63(2): 198-207. [Abstract] [Full-text]
56. Expression and functional study of estrogen receptor-related receptors in human prostatic cells and tissues.
    J Clin Endocrinol Metab, 90(3): 1830-44. [Abstract] [Full-text]
57. Curative antitumor immune response is optimal with tumor irradiation followed by genetic induction of major histocompatibility complex class I and class II molecules and suppression of Ii protein.
    Hum Gene Ther, 16(2): 187-99. [Abstract] [Full-text]
58. Virtually he@lthy: the impact of internet use on disease experience and the doctor-patient relationship.
    Qual Health Res, 15(3): 325-45. [Abstract] [Full-text]
59. Positron emission tomography and bone metastases.
    Semin Nucl Med, 35(2): 135-42. [Abstract] [Full-text]
60. Prostate cancer after exogenous testosterone replacement therapy in a patient with pituitary insufficiency.
    Scand J Urol Nephrol, 39(1): 87-8. [Abstract] [Full-text]
61. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5.
    Scand J Urol Nephrol, 39(1): 42-8. [Abstract] [Full-text]
62. Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression.
    Radiother Oncol, 74(3): 259-65. [Abstract] [Full-text]
63. Glucose deprivation increases mRNA stability of vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma.
    J Biol Chem, 280(11): 9963-72. [Abstract] [Full-text]
64. Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells.
    J Biol Chem, 280(11): 10827-33. [Abstract] [Full-text]
65. Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
    Mol Cancer Ther, 4(3): 389-98. [Abstract] [Full-text]
66. Chromosomal instability in peripheral blood lymphocytes and risk of prostate cancer.
    Cancer Epidemiol Biomarkers Prev, 14(3): 748-52. [Abstract] [Full-text]
67. Centralized blood processing for the selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability.
    Cancer Epidemiol Biomarkers Prev, 14(3): 727-30. [Abstract] [Full-text]
68. Resveratrol-induced gene expression profiles in human prostate cancer cells.
    Cancer Epidemiol Biomarkers Prev, 14(3): 596-604. [Abstract] [Full-text]
69. Geographic patterns of prostate cancer mortality and variations in access to medical care in the United States.
    Cancer Epidemiol Biomarkers Prev, 14(3): 590-5. [Abstract] [Full-text]
70. Risk of prostate cancer in a randomized clinical trial of calcium supplementation.
    Cancer Epidemiol Biomarkers Prev, 14(3): 586-9. [Abstract] [Full-text]
71. Biopsy of the prostate guided by transrectal ultrasound: relation between warfarin use and incidence of bleeding complications.
    Clin Radiol, 60(4): 459-63; discussion 457-8. [Abstract] [Full-text]
72. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen.
    Cancer Cell, 7(3): 239-49. [Abstract] [Full-text]
73. Nucleotide-excision repair and prostate cancer risk.
    Cancer Lett, 220(2): 125-35. [Abstract] [Full-text]
74. Signal transduction in prostate cancer progression.
    Clin Sci (Lond), 108(4): 293-308. [Abstract] [Full-text]
75. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    World J Urol, 23(1): 38-46. [Abstract] [Full-text]
76. Mechanisms of the development of androgen independence in prostate cancer.
    World J Urol, 23(1): 1-9. [Abstract] [Full-text]
77. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
    J Natl Cancer Inst, 97(6): 433-8. [Abstract] [Full-text]
78. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer.
    World J Urol, 23(1): 33-7. [Abstract] [Full-text]
79. High molecular mass proteome of androgen-independent prostate cancer.
    Proteomics, 5(4): 1097-112. [Abstract] [Full-text]
80. Decreased expression of e6-associated protein in breast and prostate carcinomas.
    Endocrinology, 146(4): 1707-12. [Abstract] [Full-text]
81. Chemotherapy for androgen-independent prostate cancer.
    World J Urol, 23(1): 10-3. [Abstract] [Full-text]
82. Rationale for the development and current status of calcitriol in androgen-independent prostate cancer.
    World J Urol, 23(1): 28-32. [Abstract] [Full-text]
83. The role of bisphosphonates in hormone-refractory prostate cancer.
    World J Urol, 23(1): 14-8. [Abstract] [Full-text]
84. Endothelin receptor antagonists.
    World J Urol, 23(1): 19-27. [Abstract] [Full-text]
85. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer.
    World J Urol, 23(1): 47-9. [Abstract] [Full-text]
86. Bone turnover mediates preferential localization of prostate cancer in the skeleton.
    Endocrinology, 146(4): 1727-36. [Abstract] [Full-text]
87. Characterization of linkage disequilibrium structure, mutation history, and tagging SNPs, and their use in association analyses: ELAC2 and familial early-onset prostate cancer.
    Genet Epidemiol, 28(3): 232-43. [Abstract] [Full-text]
88. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts.
    Mol Ther, 11(4): 542-52. [Abstract] [Full-text]
89. Climacteric-like disorders in prostate cancer patients treated with LHRH agonists.
    Arch Androl, 51(1): 41-8. [Abstract] [Full-text]
90. The 70 kilodalton heat shock protein is an inhibitor of apoptosis in prostate cancer.
    Int J Hyperthermia, 20(8): 835-49. [Abstract] [Full-text]
91. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
    Urol Res, 33(1): 44-50. [Abstract] [Full-text]
92. Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men.
    Prostate Cancer Prostatic Dis, 8(1): 84-90. [Abstract] [Full-text]
93. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy.
    J Clin Oncol, 23(9): 1962-8. [Abstract] [Full-text]
94. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    J Clin Oncol, 23(9): 1911-20. [Abstract] [Full-text]
95. CAG polymorphic repeat length in androgen receptor gene combined with pretreatment serum testosterone level as prognostic factor in patients with metastatic prostate cancer.
    Eur Urol, 47(4): 557-63. [Abstract] [Full-text]
96. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.
    Eur Urol, 47(4): 449-54; discussion 454-5. [Abstract] [Full-text]
97. High dose rate (HDR) brachytherapy with conformal radiation therapy for localized prostate cancer.
    Eur Urol, 47(4): 441-8. [Abstract] [Full-text]
98. Effect of a nutritional supplement containing vitamin E, selenium, vitamin c and coenzyme Q10 on serum PSA in patients with hormonally untreated carcinoma of the prostate: a randomised placebo-controlled study.
    Eur Urol, 47(4): 433-9; discussion 439-40. [Abstract] [Full-text]
99. Bicalutamide vs cyproterone acetate in preventing flare with LHRH analogue therapy for prostate cancer--a pilot study.
    Prostate Cancer Prostatic Dis, 8(1): 91-4. [Abstract] [Full-text]
100. Association between hormonal genetic polymorphisms and early-onset prostate cancer.
     Prostate Cancer Prostatic Dis, 8(1): 95-102. [Abstract] [Full-text]
101. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.
     Prostate Cancer Prostatic Dis, 8(1): 22-30. [Abstract] [Full-text]
102. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
     Prostate Cancer Prostatic Dis, 8(1): 66-8. [Abstract] [Full-text]
103. Heterocyclic amines and genotype of N-acetyltransferases as risk factors for prostate cancer.
     Prostate Cancer Prostatic Dis, 8(1): 69-74. [Abstract] [Full-text]
104. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole.
     Prostate Cancer Prostatic Dis, 8(1): 75-83. [Abstract] [Full-text]
105. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease.
     Prostate Cancer Prostatic Dis, 8(1): 54-9. [Abstract] [Full-text]
106. Risk of prostate cancer and family history of cancer: a population-based study in China.
     Prostate Cancer Prostatic Dis, 8(1): 60-5. [Abstract] [Full-text]
107. Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy.
     Prostate Cancer Prostatic Dis, 8(1): 31-5. [Abstract] [Full-text]
108. TGFBR1*6A is not associated with prostate cancer in men of European ancestry.
     Prostate Cancer Prostatic Dis, 8(1): 50-3. [Abstract] [Full-text]
109. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
     Prostate Cancer Prostatic Dis, 8(1): 7-13. [Abstract] [Full-text]
110. MUC1 expression in human prostate cancer cell lines and primary tumors.
     Prostate Cancer Prostatic Dis, 8(1): 36-44. [Abstract] [Full-text]
111. Proteome analysis of prostate cancer.
     Prostate Cancer Prostatic Dis, 8(1): 14-21. [Abstract] [Full-text]
112. Mucin-producing urothelial-type adenocarcinoma of prostate: report of two cases of a rare and diagnostically challenging entity.
     Mod Pathol, 18(4): 585-90. [Abstract] [Full-text]
113. Inhibition of tumor formation by snake venom disintegrin.
     Toxicon, 45(5): 661-9. [Abstract] [Full-text]
114. Androgen receptor activation by G(s) signaling in prostate cancer cells.
     J Biol Chem, 280(12): 11583-9. [Abstract] [Full-text]
115. Use of multiple biomarkers for a molecular diagnosis of prostate cancer.
     Int J Cancer, 114(6): 950-6. [Abstract] [Full-text]
116. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin.
     Int J Cancer, 114(6): 870-8. [Abstract] [Full-text]
117. Combined laser capture microdissection and serial analysis of gene expression from human tissue samples.
     Mod Pathol, 18(4): 577-84. [Abstract] [Full-text]
118. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer.
     Cancer Res, 65(6): 2498-504. [Abstract] [Full-text]
119. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype.
     Cancer Res, 65(6): 2441-8. [Abstract] [Full-text]
120. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells.
     Cancer Res, 65(6): 2378-86. [Abstract] [Full-text]
121. The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome.
     Cancer Res, 65(6): 2330-6. [Abstract] [Full-text]
122. Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway.
     Cancer Res, 65(6): 2303-13. [Abstract] [Full-text]
123. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth.
     Cancer Res, 65(6): 2287-95. [Abstract] [Full-text]
124. Immortalization of primary human prostate epithelial cells by c-Myc.
     Cancer Res, 65(6): 2179-85. [Abstract] [Full-text]
125. Functional Loss of the gamma-catenin gene through epigenetic and genetic pathways in human prostate cancer.
     Cancer Res, 65(6): 2130-8. [Abstract] [Full-text]
126. Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells.
     Cancer Res, 65(6): 2085-8. [Abstract] [Full-text]
127. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.
     Cancer Res, 65(6): 2082-4. [Abstract] [Full-text]
128. Ganoderma lucidum suppresses angiogenesis through the inhibition of secretion of VEGF and TGF-beta1 from prostate cancer cells.
     Biochem Biophys Res Commun, 330(1): 46-52. [Abstract] [Full-text]
129. Chemoprevention of prostate cancer.
     Crit Rev Oncol Hematol, 54(1): 1-10. [Abstract] [Full-text]
130. Prediction by quantitative histology of pathological stage in prostate cancer.
     Eur J Surg Oncol, 31(3): 309-13. [Abstract] [Full-text]
131. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer.
     Ann Oncol, 16(4): 579-84. [Abstract] [Full-text]
132. Hematopoietic cells regulate the angiogenic switch during tumorigenesis.
     Blood, 105(7): 2757-63. [Abstract] [Full-text]
133. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene.
     Br J Cancer, 92(6): 1159-64. [Abstract] [Full-text]
134. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
     Carcinogenesis, 26(4): 793-801. [Abstract] [Full-text]
135. Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate.
     Carcinogenesis, 26(4): 845-54. [Abstract] [Full-text]
136. Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
     Clin Cancer Res, 11(6): 2379-88. [Abstract] [Full-text]
137. Reg IV: a promising marker of hormone refractory metastatic prostate cancer.
     Clin Cancer Res, 11(6): 2237-43. [Abstract] [Full-text]
138. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
     Endocr Relat Cancer, 12(1): 135-48. [Abstract] [Full-text]
139. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation.
     Endocr Relat Cancer, 12(1): 119-34. [Abstract] [Full-text]
140. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
     Endocr Relat Cancer, 12(1): 109-17. [Abstract] [Full-text]
141. In situ androgen producing enzymes in human prostate cancer.
     Endocr Relat Cancer, 12(1): 101-7. [Abstract] [Full-text]
142. Primary cell cultures as models of prostate cancer development.
     Endocr Relat Cancer, 12(1): 19-47. [Abstract] [Full-text]
143. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
     Cancer, 103(7): 1375-80. [Abstract] [Full-text]
144. Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer.
     Oncogene, 24(13): 2166-74. [Abstract] [Full-text]
145. Estradiol and cognition during androgen deprivation in men with prostate carcinoma.
     Cancer, 103(7): 1381-7. [Abstract] [Full-text]
146. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions.
     Clin Chem, 51(4): 695-707. [Abstract] [Full-text]
147. Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.
     Virchows Arch, 446(3): 338-41. [Abstract] [Full-text]
148. Positron tomographic assessment of androgen receptors in prostatic carcinoma.
     Eur J Nucl Med Mol Imaging, 32(3): 344-50. [Abstract] [Full-text]
149. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.
     FEBS Lett, 579(9): 1945-50. [Abstract] [Full-text]
150. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
     Int J Cancer, 115(1): 105-13. [Abstract] [Full-text]
151. Mass spectrometry-based expression profiling of clinical prostate cancer.
     Mol Cell Proteomics, 4(4): 545-54. [Abstract] [Full-text]
152. Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma.
     BJU Int, 95(6): 881-5. [Abstract] [Full-text]
153. The effect on erectile function of 103palladium implantation for localized prostate cancer.
     BJU Int, 95(6): 847-50. [Abstract] [Full-text]
154. The assessment of patient life-expectancy: how accurate are urologists and oncologists?
     BJU Int, 95(6): 794-8. [Abstract] [Full-text]
155. Sexual, psychological and dyadic qualities of the prostate cancer 'couple'.
     BJU Int, 95(6): 780-5. [Abstract] [Full-text]
156. Testosterone recovery and changes in bone mineral density after stopping long-term luteinizing hormone-releasing hormone analogue therapy in osteoporotic patients with prostate cancer.
     BJU Int, 95(6): 776-9. [Abstract] [Full-text]
157. The incidence and treatment of lymphoceles after radical retropubic prostatectomy.
     BJU Int, 95(6): 772-5. [Abstract] [Full-text]
158. A novel technique for approaching the endopelvic fascia in retropubic radical prostatectomy, based on an anatomical study of fixed and fresh cadavers.
     BJU Int, 95(6): 766-71. [Abstract] [Full-text]
159. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
     BJU Int, 95(6): 761-5. [Abstract] [Full-text]
160. The influence of bladder neck mucosal eversion and early urinary extravasation on patient outcome after radical retropubic prostatectomy: a prospective controlled trial.
     BJU Int, 95(6): 757-60. [Abstract] [Full-text]
161. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
     BJU Int, 95(6): 751-6. [Abstract] [Full-text]
162. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer.
     Phys Med Biol, 50(7): 1483-92. [Abstract] [Full-text]
163. Quantitation of the a priori dosimetric capabilities of spatial points in inverse planning and its significant implication in defining IMRT solution space.
     Phys Med Biol, 50(7): 1469-82. [Abstract] [Full-text]
164. Dosimetric verification of IMRT treatment planning using Monte Carlo simulations for prostate cancer.
     Phys Med Biol, 50(5): 869-78. [Abstract] [Full-text]
165. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation.
     Mol Cancer Res, 3(3): 163-9. [Abstract] [Full-text]
166. The value of contrast enhanced power Doppler ultrasonography in differentiating hypoehoic lesions in the peripheral zone of prostate.
     Eur J Radiol, 54(1): 148-55. [Abstract] [Full-text]
167. Novel syngeneic pseudo-orthotopic prostate cancer model: vascular, mitotic and apoptotic responses to castration.
     Microvasc Res, 69(1): 1-9. [Abstract] [Full-text]
168. Rectal complications after modern radiation for prostate cancer: a colorectal surgical challenge.
     J Gastrointest Surg, 9(4): 461-6. [Abstract] [Full-text]
169. Serum levels of phytanic acid are associated with prostate cancer risk.
     Prostate, 63(3): 209-14. [Abstract] [Full-text]
170. Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13.
     Prostate, 63(3): 276-90. [Abstract] [Full-text]
171. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation.
     Prostate, 63(3): 215-21. [Abstract] [Full-text]
172. Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer.
     Prostate, 63(3): 231-9. [Abstract] [Full-text]
173. 5alpha-dihydrotestosterone inhibits 1alpha,25-dihydroxyvitamin D3-induced expression of CYP24 in human prostate cancer cells.
     Prostate, 63(3): 222-30. [Abstract] [Full-text]
174. Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer.
     Prostate, 63(3): 240-51. [Abstract] [Full-text]
175. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens.
     Prostate, 63(3): 252-8. [Abstract] [Full-text]
176. Is quadrant biopsy sufficient in men likely to have advanced prostate cancer? Comparison with extended biopsy.
     Pathol Oncol Res, 11(1): 40-4. [Abstract] [Full-text]
177. Prostate-specific antigen modulates the expression of genes involved in prostate tumor growth.
     Neoplasia, 7(3): 241-52. [Abstract] [Full-text]
178. Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer.
     Neoplasia, 7(3): 207-23. [Abstract] [Full-text]
179. Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer.
     Nat Genet, 37(4): 407-12. [Abstract] [Full-text]
180. 3D proton MR spectroscopic imaging of prostate cancer using a standard spine coil at 1.5 T in clinical routine: a feasibility study.
     Eur Radiol, 15(4): 653-60. [Abstract] [Full-text]
181. Three-dimensional 1H-magnetic resonance spectroscopy of the prostate in clinical practice: technique and results in patients with elevated prostate-specific antigen and negative or no previous prostate biopsies.
     Eur Radiol, 15(4): 645-52. [Abstract] [Full-text]

© 2004-2012 Prostate Cancer Research Today. All Rights Reserved.